OraPharma, Inc.
http://www.orapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From OraPharma, Inc.
Deals Shaping The Medical Industry, September 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
Valeant OTC Strategy Leverages “Relationships With Doctors”
The Canadian specialty pharma firm plans to continue bolt-on acquisitions in 2014, including more OTC products that are doctor recommended, executives say.
Valeant OTC Strategy Leverages “Relationships With Doctors”
The Canadian specialty pharma firm plans to continue bolt-on acquisitions in 2014, including more OTC products that are doctor recommended, executives say.
Acquisitive Valeant Sheds Staff As It Closes Bausch & Lomb Deal
The fast-growing, Canadian specialty pharma will shed thousands of jobs as it absorbs Bausch & Lomb, as part of an endeavor to save $800 million. CEO Mike Pearson’s note to employees describes a new organizational philosophy, with restructured management and business units.